Prostate Cancer

Prostate cancer specialists provide insights on the integration of fusion biopsy into clinical practice and how it has impacted treatment paradigms.

Lee discusses findings from a study presented at the 2024 American Urological Association Annual Meeting.

Overall, the investigators found a median PSA level of 0.02 ng/mL among transgender women with no diagnosis of prostate cancer.

"Using this as an adjunctive test after PSA screening will give physicians more information to help decide if their patient should undergo a prostate biopsy or not,” says M. Eric Hyndman, MD, PhD, FRCSC.

"Especially for prostate cancer, some of the sexual side effects, it's tough to talk about that when you're talking to your uncle or your brother who has it," says Joseph Song, MD.

“It's the next evolution of being able to provide precision care for our patients in the area of prostate cancer,” says Nitin K. Yerram, MD.

The panel discusses how fusion-guided biopsy can inform patient eligibility for focal therapy in prostate cancer.

A panel of experts on prostate cancer discuss the role for fusion-guided biopsies in active surveillance for patients with prostate cancer.

The fast track designation for BNT324/DB-1311 is supported by safety and efficacy data from an ongoing phase 1/2 trial of the ADC in patients with advanced/metastatic solid tumors.

A panel of experts on prostate cancer share strategies for monitoring patients and discuss whether to use PSMA to monitor treatment response.

Experts on prostate cancer discuss the ideal timing and frequency of PSMA-PET imaging and the role of different PSMA-PET agents.

"Looking at data, if you apply IsoPSA in a consistent manner, based on the studies published, you'll see up to a 55% reduction in unnecessary biopsies," says Jason M. Hafron, MD.

Data from SEER showed a median OS of 23.0 months between the years 2000 to 2004 in patients with mHSPC, which increased to 30.0 months in 2015 to 2019.

"Our data showed that the patient regret scores were very, very low in looking at the patients that went home the same day," says David I. Lee, MD, FACS.

Focusing on active surveillance of patients with prostate cancer, discussion centers around the role of PSMA-PET imaging and the implications of negative scans.

The panel discusses how PSMA-PET imaging informs treatment decisions for patients with prostate cancer.

Focusing on the role of systematic biopsy, the panel provides clinical insights on biopsy practice patterns after encountering suspicious-looking areas on MRI.

Experts on prostate cancer focus on the differences between fusion-guided technologies, highlighting cognitive-based and software-based fusions.

"There's obviously a huge interest in focal therapy for prostate cancer, largely because we want to try to prevent the overtreatment of prostate cancer and also develop better approaches to deliver high-quality treatment options for patients," says Timothy D. McClure, MD.

“Our trial’s preliminary major finding is that PSCA-directed CAR T cells may be effective against mCRPC," says Saul J. Priceman, PhD.

“Again, the importance of this paper to clinical practice is that it gives us real numbers on what the likelihood is of cancer in those patients with PI-RADS 3 or less,” says Jason M. Hafron, MD.

The negative margin rate was 72.8% with UnfoldAI vs 1.6% with SOC, translating to a 45-fold increase in accurately identifying cancer extent with the AI tool.

"To me, the most compelling outcome is really the quality-of-life outcomes. General quality of life as well as emotional quality of life improved in the intervention group significantly," says Jill M. Hamilton Reeves, PhD, RD, CSO.

"We concluded that to improve cost-effectiveness, prostate cancer screening strategies should focus on reducing false positives and overdiagnosis," says Roman Gulati, MS.

Steven Finkelstein, MD, FACRO, discusses PSMA-PET imaging practices for patients experiencing biochemical recurrence.